摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(5-chloro-2-isopropyl-4-methoxy-phenoxy)-pyrimidine-2,4-diamine | 1145715-92-9

中文名称
——
中文别名
——
英文名称
5-(5-chloro-2-isopropyl-4-methoxy-phenoxy)-pyrimidine-2,4-diamine
英文别名
5-(5-Chloro-4-methoxy-2-propan-2-ylphenoxy)pyrimidine-2,4-diamine
5-(5-chloro-2-isopropyl-4-methoxy-phenoxy)-pyrimidine-2,4-diamine化学式
CAS
1145715-92-9
化学式
C14H17ClN4O2
mdl
——
分子量
308.768
InChiKey
HGARQXXUVFFGNI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    480.8±55.0 °C(Predicted)
  • 密度:
    1.302±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    21
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    96.3
  • 氢给体数:
    2
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    参考文献:
    名称:
    Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X3/P2X2/3 antagonist for the treatment of pain
    摘要:
    P2X purinoceptors are ligand-gated ion channels whose endogenous ligand is ATP. Both the P2X(3) and P2X(2/3) receptor subtypes have been shown to play an important role in the regulation of sensory function and dual P2X(3)/P2X(2/3) antagonists offer significant potential for the treatment of pain. A high-throughput screen of the Roche compound collection resulted in the identification of a novel series of diaminopyrimidines; subsequent optimization resulted in the discovery of RO-4, a potent, selective and drug-like dual P2X(3)/P2X(2/3) antagonist. (C) 2009 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2009.02.003
点击查看最新优质反应信息

文献信息

  • Diaminopyrimidines as P2X3 and P2X2/3 antagonists
    申请人:Broka Allen Chris
    公开号:US20050209260A1
    公开(公告)日:2005-09-22
    Compounds and methods for treating diseases mediated by a P2X 3 and/or a P2X 2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein D, X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein.
    用于治疗由P2X3和/或P2X2/3受体拮抗剂介导的疾病的治疗化合物和方法,该方法包括向有需要的受试者施用有效量的式I化合物:或其药学上可接受的盐、溶剂化物或前药,其中D、X、Y、R1、R2、R3、R4、R5、R6、R7和R8如本文所定义。
  • Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases
    申请人:Broka Allen Chris
    公开号:US20070049609A1
    公开(公告)日:2007-03-01
    Methods for treating respiratory and gastrointestinal diseases mediated by a P2X 3 and/or a P2X 2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein D, X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein.
    用于治疗由P2X3和/或P2X2/3受体拮抗剂介导的呼吸系统和胃肠道疾病的方法,包括向有此需要的受试者施用有效量的式(I)化合物:或其药学上可接受的盐,其中D、X、Y、R1、R2、R3、R4、R5、R6、R7和R8如本文所定义。
  • Methods of Using Diaminopyrimidine P2X3 and P2X 2/3 Receptor Modulators for Treatment of Acute and Sub-Acute Cough, Urge to Cough and Chronic Cough, in Respiratory Diseases
    申请人:Afferent Pharmaceuticals, Inc.
    公开号:US20150057299A1
    公开(公告)日:2015-02-26
    Methods for treating cough, chronic cough and urges to cough associated with respiratory diseases with a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 are as defined herein.
    用P2X3和/或P2X2/3受体拮抗剂治疗咳嗽、慢性咳嗽和与呼吸系统疾病相关的咳嗽的方法,包括向需要的受试者施用化合物I的有效量或其药学上可接受的盐,其中R1和R2如本文所定义。
  • [EN] METHODS AND COMPOSITIONS FOR TREATING DISEASES AND CONDITIONS<br/>[FR] MÉTHODES ET COMPOSITIONS POUR LE TRAITEMENT DE MALADIES ET D'AFFECTIONS
    申请人:AFFERENT PHARMACEUTICALS INC
    公开号:WO2016004358A1
    公开(公告)日:2016-01-07
    Provided herein include methods and compositions for treating diseases or conditions. In some embodiments provided are methods for treating one or more diseases or conditions selected from the group consisting of hypertension, heart failure, dyspnea, and sleep apnea. In certain embodiments provided are methods that include administering a compound of formula (I) as disclosed herein. In some embodiments provided are methods that include administering a P2X3 and/or a P2X2/3 receptor antagonist.
    本文提供了用于治疗疾病或症状的方法和组合物。在某些实施例中,提供了治疗高血压、心力衰竭、呼吸困难和睡眠呼吸暂停等一种或多种疾病或症状的方法。在特定实施例中,提供了包括根据本文披露的化合物(I)的方法。在某些实施例中,提供了包括给予P2X3和/或P2X2/3受体拮抗剂的方法。
  • DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS
    申请人:Broka Chris Allen
    公开号:US20110077242A1
    公开(公告)日:2011-03-31
    Compounds and methods for treating diseases mediated by a P2X 3 and/or a P2X 2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein D, X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein.
    本发明涉及化合物和方法,用于治疗由P2X3和/或P2X2/3受体拮抗剂介导的疾病,其中所述方法包括向需要该治疗的受体中施用化合物I式的有效量,或其药学上可接受的盐、溶剂或前药,其中D、X、Y、R1、R2、R3、R4、R5、R6、R7和R8如本文所定义。
查看更多